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Background: Combination antiretroviral therapy (cART) is the current strategy to prevent mother-to-child transmission
(PMTCT) of HIV. Women initiated on cART should continue taking treatment life-long or stop after cessation of
breastfeeding depending on their CD4 cell count or on their World Health Organization (WHO) staging. Keeping
people living with HIV on treatment is essential for the success of any antiretroviral therapy (ART) programme.
There has been a rapid scale-up of cART in the PMTCT programme in South Africa. cART is supposed to be taken
life-long or until cessation of breastfeeding, but premature or unmanaged discontinuation of cART postpartum is
not unusual in South Africa and is confirmed by studies from around the world. Discontinuation of cART can lead
to mother-to-child transmission (MTCT), drug resistance and poor maternal outcomes. The extent of this problem
in the South African context however is unclear. This study aims to determine the prevalence of and identify risk
factors associated with discontinuation of cART postpartum amongst women who were initiated on antiretroviral
treatment during their index pregnancy.
Methods: An observational analytic cross-sectional study design will be conducted in six health facilities in a high
prevalence district in KwaZulu-Natal, South Africa over a period of 3 months in 2014. An interviewer-administered
questionnaire will be used to collect data from mothers who initiated cART during their index pregnancy. The
prevalence of discontinuation of cART postpartum will be measured, and the association between those who
discontinue cART postpartum and independent variables will be estimated using multivariable-adjusted prevalence
odds ratios for discontinuation.
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The national Prevention of Mother-to-Child Transmission
(PMTCT) programme was implemented in South Africa
in pilot sites in 2001 and rapidly expanded to the rest of
the country in 2002 [1]. The PMTCT programme aims to
reduce the vertical transmission of human immunodefi-
ciency virus (HIV) and has four specific elements, namely
1) primary prevention of HIV in the mother, 2) prevention
of unintended pregnancies among women living with
HIV, 3) prevention of HIV transmission from mother to
child, and 4) providing appropriate treatment and care for
women living with HIV and their families [2]. Pregnant
women living with HIV are identified during antenatal* Correspondence: claessens@ukzn.ac.za
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unless otherwise stated.care (ANC) and if positive are initiated on a cART. Redu-
cing the risk of vertical transmission during labour and
delivery requires the recommended prophylaxis and
adjustment of obstetric practices. Postpartum, the PMTCT
programme aims to reduce vertical transmission by
promoting breastfeeding with the administration of
antiretroviral therapy to keep mothers and infants
healthy through adequate follow-up visits for both
mother and infant [2].
According to the latest national PMTCT guidelines,
which were revised in March 2013, all pregnant women
living with HIV are started on cART at the time of HIV
diagnosis [2]. Women who have a CD4 count of ≤350
cells/mm3 or a WHO stage 3 or 4 of the disease are eli-
gible for life-long cART (tenofovir disoproxil fumarate
(TDF), emtricitabine (FTC)/3TC, EFV, ideally as fixed
dose combination (FDC)) whilst women with a CD4
count of >350 cells/mm3 and a WHO stage 1 or 2 willral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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feeding [2]. Women who were initiated on cART during
pregnancy do not need any additional antiretroviral
(ARV) medication during labour and delivery. The infant
regimen comprises a single dose of nevirapine (NVP) at
birth and which is continued for 6 weeks [2]. The daily
dose of NVP is only continued beyond 6 weeks in those
infants whose mothers are breastfeeding but who refused
to take cART. NVP in these infants is continued for the
duration of breastfeeding, unless the infant has been con-
firmed to be living with HIV [2].
Prior to March 2013, not all pregnant women living
with HIV were initiated on cART. [3] Depending on
their CD4 cell count and WHO staging, they were either
initiated on life-long cART or on a dual ART regimen as
prophylaxis. Although the emphasis was on cART being
life-long, experience and informal reports suggest that
discontinuation of cART postpartum is not unusual in
South Africa. There is, however, limited evidence to verify
the frequency of this practice in KwaZulu-Natal.
In April 2012, the WHO updated the ARV treatment
policy to prevent vertical transmission of HIV in pregnant
women. Three options were listed in this update: options
Aa, Bb and B+c. The revised South African PMTCT guide-
lines from 2013 are based on option B and not the alterna-
tive option B+. With option B+, all pregnant women living


















Figure 1 Conceptual framework (adapted from the WHO framewor
AIDS) [11].Description of the problem
The selected health district in KwaZulu-Natal, South
Africa has a population of 1 million [5] and an HIV
prevalence of 39.8% (95% confidence interval (CI)
35.6%–44.3%) amongst pregnant women in 2011 as re-
ported through the National Antenatal Sentinel HIV
and Syphilis Prevalence Survey [6]. The evaluation of
the effectiveness of the National PMTCT Programme
on Infant HIV showed that at 6 weeks postpartum in
KwaZulu-Natal, 29.4% (95% CI 25.5%–33.3%) of all
pregnant women living with HIV were taking cART in
2010 [7]. Reported discontinuation of cART postpartum
is not unusual and various factors have been identified
as possible causes for this. These include but are not
limited to the lack of time to process the diagnosis of
HIV before initiation on cART, status disclosure, mental
wellbeing, substance abuse and CD4 cell count. Retention
on cART is one of the core indicators of the National
Strategic Plan on HIV, STIs and TB, 2012–2016 [8].
The proportion of women who discontinue life-long
cART in the postpartum period or before complete ces-
sation of breastfeeding in this health district in
KwaZulu-Natal is not known. Continuing cART for life or
until breastfeeding has been completed leads to reduced
mother-to-child HIV transmission, decreased drug resist-
ance and improved maternal outcomes with less death,




ic: burden of 













k for adherence to long-term therapies applied to HIV and
Claessens et al. Implementation Science 2014, 9:139 Page 3 of 6
http://www.implementationscience.com/content/9/1/139There is much evidence for the efficacy of cART; how-
ever, knowing the proportion of women who discontinue
cART and the reasons for this in a real-life setting can im-
prove the implementation of the revised policy. Now that
increasingly more women are being initiated on cART, it
is important to know what can be done to retain
women in the ART programme even after delivery and
the postpartum period. Gaining better insight of women’s
intentions regarding continuation of cART as well as their
personal reasons and preferences can help inform further
updates of the PMTCT guidelines and perhaps motivate
policymakers to adopt the option B+ alternative in the fu-
ture, should the evidence support this. Furthermore, the
authors of a systematic review on unstructured treatment
interruption of ART recommended that programmes
should assess the causes and frequency of cART interrup-
tion as part of their routine monitoring [9].
Research questions
The following research questions underpin the study:
1. What is the prevalence of discontinuation of
combination antiretroviral therapy by 14 weeksFigure 2 Schematic diagram of the proposed cross-sectional study.postpartum in 2014 among women who were
initiated on antiretroviral therapy during their
pregnancy?
2. Which factors are associated with discontinuation of
cART postpartum?
Aim
The aim of this study is to determine the prevalence of
and identify risk factors associated with discontinuation
of cART by 14 weeks postpartum in women who were
initiated on treatment during their index pregnancy
and who attended immunisation clinics at one of the
four selected primary health care facilities or two com-
munity health centres in KwaZulu-Natal, South Africa
in 2014 to enable improvement of the quality of
PMTCT-related care in the public health sector in
KwaZulu-Natal.
Specific objectives
The following are the specific objectives of the study:
1. To determine the prevalence of discontinuation of
combined antiretroviral therapy by 14 weeks
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Time of discontinuation


















Highest level of education
Treatment buddy
Disclosure of status
Health of possible previous children
Health of the newborn
HIV status of the newborn
Infant feeding method
Health care worker and system Health education
Stock outs
Relationship health care provider
Planned follow-up
Travel costs to CHC
Table 1 List of variables per category (Continued)
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antiretroviral therapy during the index pregnancy
2. To determine the patient, condition, regimen,
socio-economic and health care provider and
system-related factors that are associated with
discontinuation in comparison to the group of
women who continued cART
3. To establish women’s further intentions regarding
continuation/discontinuation of cART postpartum
4. To identify preference regarding continuation/
discontinuation of cART in women who are
currently on prophylactic cART
Conceptual framework
Although this study looks at discontinuation and not at
adherence, it is mainly based on a conceptual framework
developed by the WHO to study and improve adherence
to long-term HIV/AIDS therapies. According to this
framework, there are four main groups of predictors to
adherence 1) regimen, 2) patient, 3) provider-patient re-
lationship and 4) system-of-care-related factors [11].
Based on these groups, five categories were derived and
the following framework was developed (Figure 1). It is
assumed that factors that need to be addressed when
studying or improving adherence can also be applied in
the study of discontinuation as the two are inter-related.
The exposure variables measured in this study are based
on this framework. A conceptual framework permits the
measurement of the association not only between indi-




This study will be conducted at six facilities of which
four are primary health care clinics and two are commu-
nity health centres (CHCs). The two CHCs are the two
largest primary health care sites in the urban part of the
selected district in KwaZulu-Natal. These six facilities
are situated in a variety of areas from rural to semi-rural
and urban. All six facilities offer antenatal care including
PMTCT, postnatal care and child health care including
immunisations. Included in the PMTCT services is initi-
ation on cART for all pregnant women. Based on the
District Health Information System (DHIS) data, these
facilities provide most of the immunisation services to
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cated in a high HIV prevalence district which is situated
on a major transport route connecting two of South
Africa’s biggest metros, Durban and Johannesburg.
Study design
An observational, analytic cross-sectional study design
will be used as presented in Figure 2.
Target population
The target population to which the results of this study
could be generalised is women of reproductive age, de-
fined as 15–49 years old, living with HIV, who are
pregnant and who are eligible for cART initiation in
KwaZulu-Natal according to national ART guidelines.
Study sample
A consecutive sampling method will be used in recruit-
ing the sample. From all non-probability sampling
methods, this is the best method as it seeks to include
all accessible subjects, which makes the sample more
representative of the entire population. All women who
fit the inclusion criteria at the time of data collection
will be invited to participate in the study.
Sample size
To detect a hypothesised 20% difference (translates into
a prevalence rate ratio of 1.4 or a prevalence odds ratio
of 2.3) in prevalence between those who discontinued
versus those who continued with cART (two independ-
ent proportions test) with 80% power (1-β [type 2 error
probability]) and 95% confidence interval (or 5% α error
probability [type 1]), assuming a discontinuation propor-
tion of 50% in the unexposed group (yields the largestFigure 3 Power for the difference between two independent proportpossible sample size if previous estimates are not avail-
able to suggest an estimate substantially different from
50%), yields a total required sample size of 186. Assum-
ing a non-response rate of 20% (assuming random non-
response), the final total sample size required would be
224 subjects.
List of variables
The outcome variable is the discontinuation of cART.
Table 1 presents the independent variables per category
based on the conceptual framework. Associations be-
tween discontinuation of cART and the independent var-
iables will be measured in order to identify risk factors
for the discontinuation of cART postpartum.
Data collection and analysis
The six research assistants who have been employed to
conduct the data collection through interviewer-
administered questionnaires are currently conducting
interviews in all six facilities simultaneously. Women
who attend the 14-week immunisation visit with their
infants and who have been initiated on cART in their
index pregnancy are invited to participate in the study.
Data processing and analysis will be conducted using
Stata 13.0 [StataCorp. Stata Statistical Software: Release
13. College Station, TX, USA]. Both descriptive and
analytic statistics will be employed. The variables will
be summarised by using appropriate graphs and fre-
quency distribution tables. The prevalence of discon-
tinuation of cART will be estimated along with 95%
confidence intervals. Differences in the mean values of
continuous explanatory variables by discontinuation
status will be assessed using Student’s t-test. If the data
are not-normal than the non-parametric Wilcoxonions.
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(χ2) test will be used to identify significant association
between categorical variables and the outcome. A p
value <0.05 will be considered as statistically significant.
Association between each explanatory variable and the
outcome will be tested using a bivariate logistic regres-
sion. Variables significantly associated with the out-
come at 15% level (p < 0.15) will be included in the final
multivariable model. Potential confounders will be in-
cluded in the final model. Co-linearity between covari-
ates will be assessed using variance inflation factors
(VIF). Model fit and diagnostics will also be assessed to
ensure model adequacy. The final logistic regression
model will also be evaluated in terms of its predictive
power for discontinuation of cART. Coefficients will be
exponentiated to present prevalence odds ratios and
95% confidence intervals.
Limitations
The study will not be powered to detect any difference
between the two groups below 20% with 80% power.
The rapid reduction in power when the difference drops
below 20% (i.e. p[exposed] < 0.7 versus p[unexposed] = 0.5)
can be seen in Figure 3.
Study status
Ethics approval from the University of KwaZulu-Natal
Biomedical Research Ethics Committee and the
KwaZulu-Natal Provincial Department of Health has
been obtained. Data collection started in June 2014
and will continue until the end of August 2014 at
which point the achieved sample size will be evaluated
and a decision made on whether the data collection
period will be extended or not.
Endnotes
aTreatment or prophylaxis dependent on CD4 count:
CD4 ≤ 350 cells/mm3 or WHO stage 3 or 4 regardless of
CD4 count, life-long ART. CD4 > 350 cells/mm3 and
WHO stage 1 and 2: antenatal and intra-partum prophy-
laxis (AZT, sdNVP, TDF/FTC). Extended infant NVP
syrup for breastfed infants [4].
bAll HIV-infected pregnant women initiated on ART
regardless of CD4 count: CD4 ≤ 350 cells/mm3 or WHO
stage 3 or 4, life-long ART. CD4 > 350 cells/mm3 and
WHO stages 1 and 2, stop ART after delivery if formula
feeding or after cessation of breastfeeding [4].
cLife-long ART for all HIV-infected pregnant women
regardless of CD4 count [4].
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